Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00111579 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

A Phase 2 study of Influenza, sponsored by MedImmune.

Completed
Registry status
Phase 2
Development phase
52
Enrollment target
5
Study locations

NCT00111579 is a Phase 2 study of Influenza that has completed, run by MedImmune. The registered enrollment target is 52 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00111579, a Phase 2 study of Influenza, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 2
Development phase
52 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and TIV against homotypic and heterotypic influenza virus strains.

Conditions Studied

Interventions

  • BIOLOGICAL CAIV-T
  • OTHER TIV

Study Locations (5)

Utah

  • Wee Care Pediatrics - Layton
  • Bear Care Pediatrics - Ogden
  • Alpine Pediatrics - Pleasant Grove
  • Utah Valley Pediatrics - Provo
  • Families First Pediatrics - South Jordan

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2005-05
Est. Completion 2006-01
Phase Phase 2

Sponsor

MedImmune

210 total trials

What the Registry Record Tells You About NCT00111579

The ClinicalTrials.gov registry entry for NCT00111579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which CAIV-T is the first listed.

NCT00111579 reports 5 study locations spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT00111579 about?

NCT00111579 is a clinical study titled "Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)". The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and TIV against homotypic and heterotypic influenza virus strains.

What is the current status of trial NCT00111579?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2005-05. Estimated completion is 2006-01.

What conditions does trial NCT00111579 study?

This clinical trial studies the following conditions: Influenza.

What interventions are being tested in trial NCT00111579?

The interventions under investigation include: CAIV-T (BIOLOGICAL), TIV (OTHER).

Who is sponsoring clinical trial NCT00111579?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00111579 being conducted?

This trial has 5 study locations across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Influenza

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.